Roche drug study disappoints, shares sink 5% at open

3:10 AM ET Tue, 6 June 2017

A trial from Roche combining its newer targeted drug for breast cancer with an older treatment showed only a modest benefit for women with a specific type of disease, according to data. CNBC’s Carolin Roth looks at the share price reaction.